Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting.

Abstract

In resource-limited settings, many patients, with no prior protease inhibitor (PI) treatment on a second-line, high genetic barrier, ritonavir-boosted PI-containing regimen have virologic failure